Kuala Lumpur: Olon Group, a leading global pharmaceutical CDMO, announces the appointment of J©r´me B©dier as CEO of its French entities and Andrea Conforto as MandS VP CDMO of Olon Biotech, the division dedicated to CDMO services for biologics. These appointments reinforce Olon’s strategy to expand its capabilities in Antibody-Drug Conjugates (ADCs), Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and microbial bioproduction.

According to BERNAMA News Agency, with this new leadership structure, Olon Group is accelerating the development of its fully integrated ADC offering, covering the entire value chain from Cell Line Development (CLD) to drug product manufacturing, including payload and linker production. This comprehensive approach enables biotech companies and pharmaceutical firms to access a seamless CDMO solution for next-generation targeted therapies. Olon Group is also leveraging its recent investments in its Rodano (Italy) site, which enhance its HPAPI production capabilities and align with its broader commitment to complex biopharmaceutical manufacturing.